Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 1, 2022.

Jean Hubble, MD, semi-retired neurologist and consultant, spoke with the PMD Alliance at the ATMRD Congress about the advances made in the field and her hopes for the future of therapeutics and clinical care.

The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 3 minutes]

Drs Laxman Bahroo, Rajesh Pahwa, and Robert A. Hauser share advice for neurologists treating OFF episodes in Parkinson Disease.

Robert A. Hauser, MD, MBA; Laxman Bahroo, DO; and Rajesh Pahwa, MD, review emerging therapies in development for the management of OFF episodes in Parkinson Disease.

Experts in movement disorders explore the potential role of an apomorphine infusion device in the Parkinson Disease treatment landscape for patients suffering from OFF episodes.

The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]

Among a large cohort of outpatient and inpatient individuals, the risk of Alzheimer disease, Parkinson disease, ischemic stroke, and intracerebral hemorrhage were all elevated after infection, with stroke risk increased compared with other respiratory infections.

As the individualized needs of patients are further prioritized in Parkinson disease care, the director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute shared her perspective on shared decision-making. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]

BIIB122, a selective central nervous system-penetrant small molecule inhibitor of LRRK2 is expected to be evaluated in a cohort of 640 patients with early-stage Parkinson disease.

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, highlight novel administration routes for the management of OFF episodes in patients with Parkinson disease.

Laxman Bahroo, DO, examines the effectiveness of on-demand therapies to manage OFF episodes in Parkinson disease and highlights the importance of frequent monitoring and follow-up visits.

Rajesh Pahwa, MD, comments on the different routes of administration of on-demand therapies and medication absorption for the management of OFF episodes in Parkinson disease.

Through the StrivePD ecosystem and an Apple Watch, patients, including those who have been treated with Medtronics’ deep brain stimulation device, are able to track and log their symptoms.

After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.

The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.

Here's what is coming soon to NeurologyLive®.

The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]

In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.

Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]

Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.

A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.

The study, expected to be completed in 2024, will look specifically at vocal abnormalities related to the early stages of Parkinson disease progression.